NPI: 1932150653 · TWIN FALLS, ID 83301 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 05/15/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 05/15/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 21,190 | $64K |
| 2019 | 24,208 | $129K |
| 2020 | 7,661 | $90K |
| 2021 | 830 | $68K |
| 2022 | 298 | $20K |
| 2023 | 180 | $9K |
| 2024 | 490 | $39K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 17,220 | 1,193 | $352K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 16,601 | 680 | $38K |
| J1270 | Injection, doxercalciferol, 1 mcg | 9,750 | 596 | $8K |
| J1756 | Injection, iron sucrose, 1 mg | 3,392 | 638 | $7K |
| 83970 | 1,316 | 714 | $7K | |
| A4657 | Syringe, with or without needle, each | 1,316 | 834 | $2K |
| 82728 | 601 | 361 | $1K | |
| 83550 | 575 | 346 | $1K | |
| 83540 | 579 | 348 | $859.35 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 196 | 121 | $494.46 |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 184 | 61 | $463.33 |
| 82108 | 201 | 123 | $435.23 | |
| 82746 | 223 | 138 | $290.61 | |
| 82607 | 206 | 127 | $285.91 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 168 | 25 | $277.06 |
| G0008 | Administration of influenza virus vaccine | 60 | 38 | $37.99 |
| 90674 | 28 | 18 | $28.88 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 135 | 70 | $0.00 |
| 85048 | 1,052 | 650 | $0.00 | |
| 85041 | 1,054 | 651 | $0.00 |